Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia

Journal of Molecular Diagnostics

Volumn 8, Issue 5, 2006, Pages 604-612

  Corless, Christopher L ^a,b   Harrell, Patina ^b   Lacouture, Mario ^c   Bainbridge, Troy ^b   Le, Claudia ^b   Gatter, Ken ^a   White Jr , Clifton ^b   Granter, Scott ^d   Heinrich, Michael C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BONE MARROW BIOPSY; COLON BIOPSY; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SYSTEMIC MASTOCYTOSIS; TISSUE SECTION;

EID: 33751177804     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2006.060089     Document Type: Article

References (47)

1. Heinrich MC. Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT positive malignancies. J Clin Oncol 2002, 20:1692-1703
2. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22:3813-3825
3. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, Van Oosterom AT: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40:689-695
4. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349
5. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B. Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11:4182-4190
6. Debiec-Rychter M, van Oosterom A, Marynen P: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270-279
7. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004, 90:2059-2061
8. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R, Bihl H, Leutner CC, Heinicke T, Hohenberger P: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6:249-251
9. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993, 92:1736-1744
10. Akin C, Metcalfe DD: Systemic mastocytosis. Annu Rev Med 2004, 55:419-432
11. Longley BJ, Metcalfe DD: A proposed classification of mastocytosis incorporating molecular genetics. Hematol Oncol Clin North Am 2000, 13:697-701
12. Metcalfe DD, Akin C: Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001, 25:577-582
13. Tefferi A, Pardanani A: Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004, 11:58-64
14. Valent P, Akin C, Sperr W, Mayerhofer M, Fodinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe D: Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46:35-48
15. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A: KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood epub June 1, 2006
16. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD: Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am 2003, 17:1227-1241
17. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD: Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000, 28:140-147
18. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J: Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998, 111:1227-1231
19. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Fodinger M: Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001, 113:357-364
20. Longley BJJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999, 96:1609-1614
21. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560-10564
22. Yanagihori H, Oyama N, Nakamura K, Kaneko F: c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005, 7:252-257
23. Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bultmann B: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003, 162:737-746
24. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214
25. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A: F1P1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004, 104:3038-3045
26. Pardanani A, Tefferi A: Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders, Leuk Res 2004, 28(Suppl 1):47-52
27. Frost MJ, Ferrao PT, Hughes TP, Ashman LK: Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002, 1:1115-1124
28. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regutatory-type mutations. Blood 2002, 99:1741-1744
29. Zermati Y, De Sepulveda P, Feger F. Letard S, Kersual J, Casteran N, Gorochov G, Dy M, Ribadeau DA, Dorgharn K, Parizot C, Bieche Y, Vidaud M, Lortholary O, Arock M, Hermine O, Dubreuil P: Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003, 22:660-664
30. Hennessy B. Giles F, Cortes J, O'Brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S: Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience Am J Hematol 2004, 77:209-214
31. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM: Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res 2004, 28:421-422
32. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A: Imatinib for systemic mast-cell disease. Lancet 2003, 362:535-536
33. Worobec AS, Semere T, Nagata H, Metcalfe DD: Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998, 83:2120-2129
34. Droogendijk HJ, Kluin-Nelemans HJ, Van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006, 107:345-351
35. Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L: KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925
36. Goemans BF, Zwaan C, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542
37. Cairoli R, Beghini A, Morello E, Grillo G, Montillo M, Larizza L, Morra E: Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations. A report of three cases. Leuk Res 2005, 29:397-400
38. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160:1567-1572
39. McKinzie PB, Parsons BL: Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res 2002, 517:209-220
40. Schittenhelm MM, Shiraga S. Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW. Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481
41. Kemmer K. Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC: KIT mutations are common in testicular seminomas. Am J Pathol 2004, 164:305-313
42. Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC: Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 2004, 18:864-871
43. Parsons BL, Culp SJ, Manjanatha MG, Heflich RH: Occurrence of H-ras coclon 61 CAA to AAA mutation during mouse liver tumor progression. Carcinogenesis 2002, 23:943-948
44. Dominguez PL, Kolodney MS: Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 2005, 24:6830-6834
45. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 2006, 107:752-759
46. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106:2865-2870
47. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106:721-724